» Authors » Zabih Warraich

Zabih Warraich

Explore the profile of Zabih Warraich including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 65
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaudhary N, Warraich F, Warraich Z, Warraich S, Anwer F
Cureus . 2019 Nov; 11(10):e5813. PMID: 31737455
We present an unusual case of hyponatremia in an ambulatory hypothyroid patient and review related published literature on PubMed including, original articles, reviews and case reports that describe or refute...
2.
Warraich Z, Tenneti P, Thai T, Hubben A, Amin H, McBride A, et al.
Biol Blood Marrow Transplant . 2019 Sep; 26(3):e55-e64. PMID: 31557532
Relapse after stem cell transplantation for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) remains a significant challenge. In this systematic review, we compare survival outcomes of second-generation tyrosine kinase inhibitors...
3.
Fraz M, Warraich F, Warraich S, Tariq M, Warraich Z, Khan A, et al.
Crit Rev Oncol Hematol . 2019 Apr; 137:18-26. PMID: 31014512
Multiple Myeloma (MM) is primarily a disease of old age with a median age of sixty-nine years at diagnosis. The development of novel therapies for induction and use of autologous...
4.
Tenneti P, Zahid U, Iftikhar A, Yun S, Sohail A, Warraich Z, et al.
Sarcoma . 2018 Jul; 2018:2640674. PMID: 29973774
Background: Relapsed Ewing's sarcoma (RES) is an aggressive malignancy with poor survival. Although high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) given after conventional chemotherapy (CC) has shown survival...
5.
Siyahian A, Malik S, Mushtaq A, Howe C, Majeed A, Zangeneh T, et al.
Biol Blood Marrow Transplant . 2018 Mar; 24(7):1483-1489. PMID: 29545185
Patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) are at a very high risk of hepatitis B virus reactivation (HBVr). Lamivudine is commonly used as prophylaxis against HBVr in high-risk...
6.
Sohail A, Mushtaq A, Iftikhar A, Warraich Z, Kurtin S, Tenneti P, et al.
Immunotherapy . 2018 Feb; 10(4):265-282. PMID: 29421983
We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal...